LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 21, 2005--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that it has received notice from the U.S. Food & Drug Administration (FDA) that the Supplemental New Drug Application (sNDA) for Cubist's antibiotic CUBICIN(R) (daptomycin for injection) has been accepted and has been granted priority review status. The FDA grants priority review to products it believes represent a therapeutic advance over existing medicines. By granting priority review status to CUBICIN, the FDA has established a target date to act on the sNDA filing by March 24, 2006.
